Skip to content

Mechanism of resistance to CDK4/6 inhibitors in breast cancer

Mechanism of resistance to CDK4/6 inhibitors in breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092207
Enrollment
Unknown
Registered
2024-11-12
Start date
2024-11-12
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Breast cancer treated with CDK4/6 inhibitor:None
Ordinary breast cancer patients:None

Sponsors

Breast Surgery of the First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1: Female patients aged 18 years or older and 85 years or younger. 2: For early, local progress or advanced breast cancer confirmed by puncture or surgery pathology, imaging has clear and measurable lesions.

Exclusion criteria

Exclusion criteria: 1: Life expectancy and medication duration are less than 3 months; 2: Suffering from severe uncontrolled systemic diseases, or evidence or medical history of visceral crisis, central nervous system metastasis; (Visceral crisis is defined as several organ dysfunction confirmed by symptoms, signs, laboratory tests, and rapid disease progression. Visceral crisis does not simply refer to the presence of visceral metastasis, but rather to critical visceral conditions that require rapid and effective treatment to control disease progression, especially when the opportunity for chemotherapy is lost after progression.); 3: Suffering from serious accompanying diseases or other accompanying diseases that may interfere with the study, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study.

Design outcomes

Primary

MeasureTime frame
progression-free survival;Expression of DKK1;Expression of CDK6;

Secondary

MeasureTime frame
Overall survival;Expression of CD3;Expression of CD8;Expression of CD56;Expression of CD68;Expression of FOXP3;Expression of PD1;Expression of PD-L1;Expression of p-RB;

Countries

China

Contacts

Public ContactBo Chen

The First Hospital of China Medical University

bochen@cmu.edu.cn+86 159 0402 5211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026